ArticleBMC infectious diseases2018
Lactobacillus paracasei feeding improves the control of secondary experimental meningococcal infection in flu-infected mice.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies.European journal of nutrition · 2021Pooled it
- Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence.Viruses · 2026Review
- Human breast milk-derived Limosilactobacillus fermentum strains modulate hBD-2 expression against Neisseria meningitidis infection through the TLR-2/p38-MAPK/NF-κB pathway.World journal of microbiology & biotechnology · 2025Article
- Understanding the Dynamics of Human Defensin Antimicrobial Peptides: Pathogen Resistance and Commensal Induction.Applied biochemistry and biotechnology · 2024Review
- Effect of Mixed Probiotics on Alleviating H1N1 Influenza Infection and Regulating Gut Microbiota.Foods (Basel, Switzerland) · 2024Article
- Article
- Vertebrate and Invertebrate Animal and New In Vitro Models for StudyingPathogens (Basel, Switzerland) · 2023Review
- Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice.BMC microbiology · 2021Article
- The gut microbiome: a missing link in understanding the gastrointestinal manifestations of COVID-19?Cold Spring Harbor molecular case studies · 2021Review
- Modulation of Human Beta-Defensin 2 Expression by Pathogenic Neisseria meningitidis and Commensal Lactobacilli.Antimicrobial agents and chemotherapy · 2021Article
- Kawasaki disease: pathophysiology and insights from mouse models.Nature reviews. Rheumatology · 2020Review
- Probiotic Characterization of Lactobacillus paracasei subsp. paracasei KNI9 Inhibiting Adherence of Yersinia enterocolitica on Caco-2 Cells In Vitro.Probiotics and antimicrobial proteins · 2020Article
- Difference in virulence between Neisseria meningitidis serogroups W and Y in transgenic mice.BMC microbiology · 2020Article
- Viral Infections, the Microbiome, and Probiotics.Frontiers in cellular and infection microbiology · 2020Review
- Perspectives on Probiotics and Bronchopulmonary Dysplasia.Frontiers in pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe use of probiotics to improve anti-microbial defence, such as for influenza infections, is increasingly recommended. However, no data are available on the effect of probiotics on flu-associated secondary bacterial infections. There is strong evidence of a spatiotemporal association between influenza virus infection and invasive Neisseria meningitidis. We thus investigated the effect of feeding mice Lactobacillus paracasei CNCM I-1518 in a mouse model of sequential influenza-meningococcal infection.
methodsWe intranasally infected BALB/c mice with a strain of influenza A virus (IAV) H3N2 that was first adapted to mice. Seven days later, a secondary bacterial infection was induced by intranasal administration of bioluminescent N. meningitidis. During the experiment, mice orally received either L. paracasei CNCM I-1518 or PBS as a control. The effect of L. paracasei administration on secondary bacterial infection by N. meningitidis was evaluated.
resultsOral consumption of L. paracasei CNCM I-1518 reduced the weight loss of infected mice and lowered the bioluminescent signal of infecting meningococci. This improvement was associated with higher recruitment of inflammatory myeloid cells, such as interstitial monocytes and dendritic cells, to the lungs.
conclusionsOur data highlight the role of the gut-lung axis. L. paracasei CNCM I-1518 may boost the defence against IAV infection and secondary bacterial infection, which should be further studied and validated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.